Table 3.

Per-patient costs (euro) throughout the whole study perioda

Standard-Dose RATG(n = 16)Low-Dose RATG(n = 17)
Study drug5,344 ± 4903,737 ± 171b
Initial hospitalization11,325 ± 1,65010,658 ± 991
Subsequent hospitalizations2,081 ± 1,0091,941 ± 907
Dialysis therapy174 ± 41135 ± 32
Red blood cell transfusions190 ± 5549 ± 21c
CMV prophylaxis and treatment of infectious episodes1,061 ± 166480 ± 109b
Total18,094 ± 1,62515,059 ± 1,029
  • a Data are expressed as mean ± SE.

  • b P = 0.01,

  • c P < 0.01 versus standard-dose RATG.